BioSpace News Archive

Kristiina Vuori, M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery Institute

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced an amendment to its existing debt facility with CRG Servicing LLC.

Butterfly Network forms a landmark collaboration with the American College of Cardiology to revolutionize cardiovascular care using innovative point-of-care ultrasound imaging.

Bausch Health Companies Inc. provided a preliminary update on its third-quarter 2020 financial results and the pace of its business recovery from the COVID-19 pandemic.

--Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer patients -- [08-October-2020] SAN FRANCISCO , Oct. 8, 2020 /PRNewswire/ -- Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germlin

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Medicare Administrative Contractor, Palmetto GBA MolDx, has issued a final expanded local coverage determination (LCD) for the company’s Decisi

Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD − Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M − Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing s

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for dehydrated alcohol injection

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)